undamentalytics Newsletter
Sign in

Privia Health Group, Inc. (PRVA) stock

Add to watchlist

Add holding +

NASDAQ: PRVA Nasdaq Health Care Services Next results ~November 5, 2026

C Fundamentals grade

Privia Health Group, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$18

Cash-flow model

Base case. Range ~$14–$23 across our lower- and higher-growth cases (15%–25% a year).

Price vs value

Modestly overvalued

The price is inside our value range, 19% above our base value.

Price used: $21.28, November 2, 2026

Privia Health Group, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 4 selling0 purchases and 40 sales by directors and officers, last 12 monthsInsider trades
  • Funds155 adding, 136 cuttingOf 46 active managers that changed their stake, 20 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Privia Health Group files

Where Privia Health stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $2.36bn, up 24.1% on a year earlier, slower than the 24.7% growth a quarter earlier. That growth ranks 5 of 21 among the health care services companies we cover. Free-cash-flow margin held at 5.6%. The diluted share count is up 2.7% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks. Our cash-flow model value is $18.96 a share, against a share price of $22.04. At that price, our model says the market is pricing in about 23.4% a year of cash-flow growth for five years, faster than the 19.5% a year revenue growth it has delivered.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Privia Health Group, Inc.'s trailing-twelve-month revenue grew 24.1% year on year, with a free-cash-flow margin of 5.6%. Where it lags: days sales outstanding of 89 days ranks 29 of 31 health care services companies we cover.

Our discounted-cash-flow model values the business at ~$18 per share in the base case (~$14–$23 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 42.7% while net income grew 89.5%: a 47pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 24.1% over the last 12 months, against a median of 7.3% for health care services companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.4bn.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 2.7% in a year.
  • High earnings multiple. The shares trade at 99 times the last 12 months' earnings, so expectations are demanding.
  • Insiders selling. 4 insiders sold $22M of stock over the past 365 days and none bought (87% under pre-set trading plans).
  • Below peers: days sales outstanding. Days sales outstanding of 89 days ranks 29 of 31 health care services companies we cover (median 39 days).
  • Below peers: stock pay as % of revenue. Stock pay as % of revenue of 3.2% ranks 27 of 35 health care services companies we cover (median 0.9%).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
$0.19 against an average estimate of $0.24: missed by 22.2%
Revenue
$633m, up 21.4% on a year earlier
Share reaction
-6.3% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate $0.24

Privia Health Group's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.9%
  • 1 week-4.0%
  • 1 month+4.8%
  • This year-10.2%
  • 1 year-12.4%
  • 5 years-19.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.4B
Operating margin
1.9%
Net margin
1.2%
EPS (TTM, diluted)
$0.22

Growth

Revenue growth
+24.1%
Change in growth rate
−0.6 pts
Share count change
+2.7%

Cash

Free cash flow (TTM)
$131M
FCF margin
5.6%
Stock pay % of revenue
3.2%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results
  3. Leadership
  4. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Privia Health Group, Inc. valuation models and calculator

What the price is pricing in

The share price implies about 21.5% a year of cash-flow growth for five years.That is close to the 19.5% a year revenue growth Privia Health Group has delivered.

  • Priced in21.5%
  • Last 12 months24.1%
  • 3 years a year16.1%
  • 5 years a year19.5%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($21.18, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$18
Price used
$21.18close November 3, 2026
Implied change
▼ 15%
Uncertainty
Low

How we got here: a discounted-cash-flow model of Privia Health Group, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($47.3M, FY2026 Q2 TTM), growing 12.8% and 16.6% in the next two years (forecasts, guidance and its record), then back to 20% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$14–~$23 ; that spread sets a 15% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Privia Health Group, Inc.'s free cash flow after stock-based pay ( $47.3M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Privia Health Group, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.6%: the 10-year Treasury yield (4.9%) plus a beta of 0.81 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$18 ~$14–$23 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$19 ~$15–$30 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$1.3 ~$0.7–$2.4 Left out: out of range vs price (0.06x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity below long-run growth
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$18 ~$18–$19 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Privia Health Group, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −22%
  • Revenue growth 5 points higher ▲ +29%
  • Free-cash-flow margin 1 point lower ▼ −17%
  • Last year's free-cash-flow margin change, if it persists ▲ +14%
  • Discount rate 1 point higher ▼ −15%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $8$10$13$16$20$26
8.5% $7$8$10$13$16$20
10% $6$7$9$11$13$16

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$25.87$22.71$23.03$19.55$23.71$21.28
Market value$2.7bn$2.5bn$2.9bn$2.5bn$3.1bn$2.8bn
+ Net debt (− = net cash)−$287m−$348m−$390m−$491m−$480m−$412m
Enterprise value$2.4bn$2.2bn$2.5bn$2.0bn$2.6bn$2.4bn
Multiples
Price / sales 2.8x1.9x1.7x1.4x1.4x1.2x
Price / earnings ——124.4x170.7x133.3x98.8x
Price / free cash flow 48.9x53.4x35.6x22.5x18.7x21.2x
EV / EBITDA ——91.3x81.0x58.4x41.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

21 /100

Weak moat

How hard Privia Health Group's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median 1.3% of total assets over 6 years.

  • Durability 0 / 20

    Operating margin has been a median 0.8%; its worst year was -20.1%.

  • Cash conversion 12 / 20

    Free cash flow was positive in 6 of 6 years, at a median 4.6% of revenue.

  • Discipline 8 / 20

    The diluted share count rose 33.6% over five years; stock-based pay has been a median 3.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (26 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $611m and EPS of $0.24 (range $0.18 to $0.32) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.89 −10% $2.5bn +16%
Next $1.06 +20% $2.7bn +10%

Next year's EPS estimate has moved −3.1% in 90 days, across 10 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.24 $0.19 −22.2%
Mar 2026 $0.25 $0.19 −24.1%
Dec 2025 $0.19 $0.25 +30.2%
Sept 2025 $0.22 $0.29 +33.7%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Privia Health Group, Inc.'s revenue by +12.8% next year and +16.6% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+9.4%, weight 68%) and the company's own record (+20.0%, weight 32%) . How the weights are set.

Analyst recommendations

18 analysts, Oct 2026
Buy1794%
Hold16%
Sell00%

Monthly trend

  1. Oct 202651218
  2. Sep 202651218
  3. Aug 202651319
  4. Jul 2026513220

Counts of recommendations published by analysts covering Privia Health Group, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.7%
of tradable shares
Days to cover
4.48
at average volume
Short interest, 1 month
+6%
to September 30, 2026
Held by institutions
99%
of shares
Held by insiders
6.2%
of shares
Employees
1,226
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −12.4%

$24.30 on October 31, 2025 to $21.28

ThenNowEffect
Revenue (last 12 months) $1.9bn $2.4bn +24.1%
Net margin 0.8% 1.2% +52.7%
P/E multiple n/m 98.8x −52.5%
Share count 127m 131m −2.6%

Biggest factor: p/e multiple.

Last 3 years −9.5%

$23.52 on November 3, 2023 to $21.28

ThenNowEffect
Revenue (last 12 months) $1.5bn $2.4bn +56.5%
Net margin 2.3% 1.2% −47.1%
P/E multiple 82.1x 98.8x +20.2%
Share count 119m 131m −9.0%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
PRVA−12%+1%−15%+21%−10%
Industry peers (median)−28%+8%−6%−9%+15%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
PRVA50%50%42%58%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
PRVA−48%−32%−32%−27%−32%
S&P 500−25%−10%−8%−19%−9%

Worst fall since April 28, 2021: 67% from June 28, 2021 to May 20, 2024. Getting back needed a 206% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$19.10 – $28.10
From 52-week high
−24.3%
vs 50-day average
+1.9%
vs 200-day average
−6.1%
Volatility (1 year)
32%
Beta vs S&P 500
0.57

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±5.5%
After a week
8 up, 4 down
typical move ±5.8%
After a month
4 up, 8 down
typical move ±7.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −6.3% +0.5% −9.2% −13.8%
May 7, 2026 −3.9% +0.5% −3.1% −10.8%
February 26, 2026 +4.9% −1.0% +5.3% −11.6%
November 6, 2025 −6.4% −1.0% −5.1% −5.6%
August 7, 2025 +4.0% +0.7% +4.7% +19.3%
May 8, 2025 +7.3% +0.6% +6.8% −0.3%
February 27, 2025 +3.8% −0.1% +5.0% −6.1%
November 7, 2024 +0.7% +1.2% +2.5% +1.7%
August 8, 2024 +4.4% +2.8% +6.9% +2.2%
May 9, 2024 −4.7% +0.7% −9.9% −10.1%
February 27, 2024 +9.4% +0.1% +5.4% −2.2%
November 3, 2023 +9.7% +1.1% +5.9% +1.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Privia Health Group, Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Privia Health Group, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Privia Health Group, Inc.
$1.4B $1.6B $1.8B $2B $2.2B $2.4B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.6B Revenue (TTM), FY23 Q4: $1.7B Revenue (TTM), FY24 Q1: $1.7B Revenue (TTM), FY24 Q2: $1.7B Revenue (TTM), FY24 Q3: $1.7B Revenue (TTM), FY24 Q4: $1.7B Revenue (TTM), FY25 Q1: $1.8B Revenue (TTM), FY25 Q2: $1.9B Revenue (TTM), FY25 Q3: $2B Revenue (TTM), FY25 Q4: $2.1B Revenue (TTM), FY26 Q1: $2.2B Revenue (TTM), FY26 Q2: $2.4B $2.4B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.6B
FY23 Q4 $1.7B
FY24 Q1 $1.7B
FY24 Q2 $1.7B
FY24 Q3 $1.7B
FY24 Q4 $1.7B
FY25 Q1 $1.8B
FY25 Q2 $1.9B
FY25 Q3 $2B
FY25 Q4 $2.1B
FY26 Q1 $2.2B
FY26 Q2 $2.4B
Revenue growth, TTM YoY Privia Health Group, Inc.
0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 24.8% Revenue growth, TTM YoY, FY23 Q4: 22.2% Revenue growth, TTM YoY, FY24 Q1: 18.0% Revenue growth, TTM YoY, FY24 Q2: 12.5% Revenue growth, TTM YoY, FY24 Q3: 8.5% Revenue growth, TTM YoY, FY24 Q4: 4.7% Revenue growth, TTM YoY, FY25 Q1: 6.8% Revenue growth, TTM YoY, FY25 Q2: 12.1% Revenue growth, TTM YoY, FY25 Q3: 19.0% Revenue growth, TTM YoY, FY25 Q4: 22.3% Revenue growth, TTM YoY, FY26 Q1: 24.7% Revenue growth, TTM YoY, FY26 Q2: 24.1% 24.1%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 24.8%
FY23 Q4 22.2%
FY24 Q1 18.0%
FY24 Q2 12.5%
FY24 Q3 8.5%
FY24 Q4 4.7%
FY25 Q1 6.8%
FY25 Q2 12.1%
FY25 Q3 19.0%
FY25 Q4 22.3%
FY26 Q1 24.7%
FY26 Q2 24.1%
Operating margin (TTM) Privia Health Group, Inc.
0.5% 1% 1.5% 2% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 1.4% Operating margin (TTM), FY23 Q4: 1.2% Operating margin (TTM), FY24 Q1: 0.9% Operating margin (TTM), FY24 Q2: 0.8% Operating margin (TTM), FY24 Q3: 0.8% Operating margin (TTM), FY24 Q4: 1.0% Operating margin (TTM), FY25 Q1: 1.2% Operating margin (TTM), FY25 Q2: 1.0% Operating margin (TTM), FY25 Q3: 1.4% Operating margin (TTM), FY25 Q4: 1.6% Operating margin (TTM), FY26 Q1: 1.6% Operating margin (TTM), FY26 Q2: 1.9% 1.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 1.4%
FY23 Q4 1.2%
FY24 Q1 0.9%
FY24 Q2 0.8%
FY24 Q3 0.8%
FY24 Q4 1.0%
FY25 Q1 1.2%
FY25 Q2 1.0%
FY25 Q3 1.4%
FY25 Q4 1.6%
FY26 Q1 1.6%
FY26 Q2 1.9%
FCF margin (TTM) Privia Health Group, Inc.
2% 4% 6% 8% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 2.9% FCF margin (TTM), FY23 Q4: 4.9% FCF margin (TTM), FY24 Q1: 3.6% FCF margin (TTM), FY24 Q2: 5.2% FCF margin (TTM), FY24 Q3: 5.7% FCF margin (TTM), FY24 Q4: 6.3% FCF margin (TTM), FY25 Q1: 6.6% FCF margin (TTM), FY25 Q2: 4.8% FCF margin (TTM), FY25 Q3: 5.4% FCF margin (TTM), FY25 Q4: 7.7% FCF margin (TTM), FY26 Q1: 6.1% FCF margin (TTM), FY26 Q2: 5.6% 5.6%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 2.9%
FY23 Q4 4.9%
FY24 Q1 3.6%
FY24 Q2 5.2%
FY24 Q3 5.7%
FY24 Q4 6.3%
FY25 Q1 6.6%
FY25 Q2 4.8%
FY25 Q3 5.4%
FY25 Q4 7.7%
FY26 Q1 6.1%
FY26 Q2 5.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Privia Health Group took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $2.1B
  2. Selling, general and admin $165M · 7.8%
  3. Other operating costs $1.9B · 90.6%
  4. Operating income $34.2M · 1.6%
  5. Income tax $14.2M · 0.7%
  6. Net income $22.9M · 1.1%

Shares of revenue. Source: Privia Health Group's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 786 817 966 1,357 1,658 1,736 2,123 2,358
EBITDA 17 27 −215 −15 27 24 44 57
Operating income 16 25 −217 −19 21 17 34 45
Net income 8 31 −188 −9 23 14 23 28
Diluted EPS $0.09 $0.33 −$1.83 −$0.08 $0.19 $0.11 $0.18 $0.22
Growth (year on year)
Revenue — +3.9% +18.3% +40.4% +22.2% +4.7% +22.3% +24.1%
EBITDA — +55.7% −889.7% — — — — —
Operating income — +58.0% −956.7% — — — — —
Net income — — −702.5% — — — — —
Diluted EPS — — −654.5% — — — — —
Margins
EBITDA margin 2.2% 3.3% −22.2% −1.1% 1.6% 1.4% 2.1% 2.4%
Operating margin 2.0% 3.1% −22.5% −1.4% 1.2% 1.0% 1.6% 1.9%
Net margin 1.0% 3.8% −19.5% −0.6% 1.4% 0.8% 1.1% 1.2%
Free-cash-flow margin 2.4% 4.7% 5.6% 3.5% 4.9% 6.3% 7.7% 5.6%
Cash flow
Cash from operations 24 39 55 47 81 109 163 131
Capital spending 6 0 1 0 0 0 0 0
Free cash flow 19 39 55 47 81 109 163 131
Stock-based pay 0 0 254 67 37 57 71 76
Free cash flow after stock pay 18 38 −199 −20 44 53 92 55
Balance sheet
Cash 47 85 321 348 390 491 480 412
Total debt 0 34 33 0 0 0 0 0
Net debt (negative = net cash) −47 −51 −287 −348 −390 −491 −480 −412
Diluted shares 96m 96m 103m 111m 125m 126m 129m 131m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $1.5bn
Short-term assets $1.0bnLonger-term assets $463m
What it owes, and who funded it · $1.4bn
Short-term liabilities $634mLonger-term liabilities $16mShareholders' equity $782m
  • Short-term assets cover short-term liabilities $1.0bn of assets due within a year against $634m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.0bn short-term assets against $16m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Privia Health Group, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2.7%
year over year
Days sales outstanding
89 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated PRVA RDNT HIMS AVAH EVH CHE Median
Revenue, last 12 months $2.4bn $2.3bn $2.6bn $2.6bn $2.1bn $2.7bn $1.2bn
Revenue growth, last 12 months 24.1% 18.9% 28.0% 19.5% −4.5% 5.2% 7.3%
Revenue growth, 3-year average 16.1% 14.1% 53.7% 12.4% 8.7% 6.1% 11.3%
Revenue growth, latest quarter 21.4% 25.0% 38.2% 13.7% 46.9% 10.6% 8.5%
Gross margin — 13.4% 68.4% 32.3% 17.2% 33.5% 27.9%
Operating margin 1.9% 3.1% −6.0% 10.5% −20.4% 13.9% 2.3%
Operating margin, 3-year average 1.2% 4.4% 0.5% 7.0% −8.0% 14.4% 2.3%
Net margin 1.2% −0.9% −5.5% 10.6% −24.1% 10.6% 1.2%
Cash from operations / revenue 5.6% 13.7% 10.2% 6.5% 2.6% 13.6% 6.1%
Free-cash-flow margin 5.6% 3.2% 2.4% 6.0% −2.7% 11.1% 5.1%
Free-cash-flow margin, 3-year average 5.2% 3.7% — 3.2% −2.3% 11.6% 3.6%
Stock pay / revenue 3.2% 2.6% 6.0% 0.7% 2.0% — 1.1%
Change in share count 2.7% 0.1% 0.3% 11.4% −2.4% −8.3% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 24.1% 7.3% 10 of 41
Change in growth rate Growth -0.6pp +1.1pp 29 of 41
Operating margin Profitability 1.9% 2.6% 22 of 40
Net margin Profitability 1.2% 1.2% 20 of 41
Free-cash-flow margin Cash generation 5.6% 5.1% 17 of 40
Stock pay as % of revenue Cash generation 3.2% 0.9% 27 of 35
Change in share count Balance sheet 2.7% 0.4% 28 of 39
Days sales outstanding Balance sheet 89 days 39 days 29 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
FFS Patient Care $1.4B 64.0% ▲ 18.7%
Capitated Revenue $308M 14.5% ▲ 44.8%
Shared Savings $235M 11.0% ▲ 31.0%
FFS Administrative Services $137M 6.4% ▲ 9.2%
Care Management Fee PMPM $73.1M 3.4% ▲ 14.2%
Other Revenue $9.2M 0.4% ▲ 7.4%
Administrative Service $3.5M 0.2% ▲ 94.4%

From Privia Health Group, Inc.'s 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$3.2B
Institutions reporting
298
Shares held vs prior quarter
▼ 1.1%
Positions opened / closed
41 / 34

Top buyers and sellers, Q2 2026: 155 institutions bought and 136 sold ; the biggest buyer was Blackrock, Inc (+2.3M shares) and the biggest seller Van Berkom & Associates Inc (−4.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $551M 21.4M 17.3% ▲ 12.3%
FMR LLC $331M 12.8M 10.4% ▼ 1.5%
Durable Capital Partners LP $299M 11.6M 9.4% ▼ 3.7%
Vanguard Portfolio Management LLC $169M 6.6M 5.3% ▲ 4.6%
Rubicon Founders LLC $154M 6.0M 4.8% ▲ 0.4%
Vanguard Capital Management LLC $133M 5.2M 4.2% ▲ 3.0%
State Street Corp $126M 4.9M 4.0% ▲ 9.3%
Van Berkom & Associates Inc. $95.5M 3.7M 3.0% ▼ 54.2%
Geode Capital Management, LLC $80.6M 3.1M 2.5% ▲ 8.1%
Riverbridge Partners LLC $77.2M 3.0M 2.4% ▼ 23.5%
Bank Of New York Mellon Corp $74.4M 2.9M 2.3% ▼ 1.7%
Principal Financial Group Inc $66.6M 2.6M 2.1% ▼ 5.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Privia Health Group, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $22.2M 40 trades by 4 insiders · 87% under pre-set plans
Net ▼ $22.2M net selling
Insider Date Trade Shares Price Value
Mountcastle David EVP & Chief Financial Officer July 9, 2026 Sell pre-set plan 21,275 $27.67 $588,679
Mountcastle David EVP & Chief Financial Officer July 7, 2026 Sell pre-set plan 600 $27.57 $16,542
Morris Matthew Shawn Director July 6, 2026 Sell pre-set plan 53,722 $27.24 $1.5M
Mountcastle David EVP & Chief Financial Officer July 2, 2026 Sell pre-set plan 24,734 $27.50 $680,185
Morris Matthew Shawn Director July 2, 2026 Sell pre-set plan 59,037 $27.33 $1.6M
Morris Matthew Shawn Director July 1, 2026 Sell pre-set plan 45,634 $26.52 $1.2M
Morris Matthew Shawn Director July 1, 2026 Sell pre-set plan 37,041 $26.93 $997,514
Morris Matthew Shawn Director June 30, 2026 Sell pre-set plan 52,823 $25.72 $1.4M
Morris Matthew Shawn Director June 29, 2026 Sell pre-set plan 63,212 $25.33 $1.6M
Mountcastle David EVP & Chief Financial Officer June 26, 2026 Sell pre-set plan 17,196 $25.18 $432,995
Morris Matthew Shawn Director June 26, 2026 Sell pre-set plan 88,110 $25.33 $2.2M
Mehrotra Parth Chief Executive Officer May 12, 2026 Sell pre-set plan 15,647 $22.64 $354,248

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 26, 2026
  • November 6, 2025
  • August 7, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Privia Health Group, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Privia Health Group, Inc. in brief

What does Privia Health Group, Inc. do?
Privia Health Group, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Privia Health Group, Inc.'s stock ticker?
Privia Health Group, Inc. trades under the ticker PRVA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Privia Health Group, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Privia Health Group, Inc. reported revenue of $2.4B, 24.1% higher than a year earlier, according to its SEC filings.
What is Privia Health Group, Inc.'s free cash flow?
Privia Health Group, Inc.'s free-cash-flow margin is 5.6% of revenue over the trailing twelve months, ranking 17 of the 40 health care services companies we cover.
What is Privia Health Group, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Privia Health Group, Inc.'s free cash flow after stock-based pay gives ~$18 per share in the base case, and ~$14–$23 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Privia Health Group, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., FMR LLC and Durable Capital Partners LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Privia Health Group, Inc.'s market cap?
On November 2, 2026, Privia Health Group, Inc.'s market capitalisation was about $2.8B, with a price-to-earnings ratio of 98.8 and net debt of -$412M. Market figures come from third-party market data and may be delayed.
Who are Privia Health Group, Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Privia Health Group, Inc. are Radnet, Inc., Hims & Hers Health, Inc., Aveanna Healthcare Holdings, Inc., Evolent Health, Inc. and Chemed Corp. The side-by-side comparison below sets their revenue, margins and growth against Privia Health Group, Inc.'s.
Are insiders buying or selling Privia Health Group, Inc. stock?
Over the last 12 months, Privia Health Group, Inc.'s directors and officers reported 0 open-market purchases and 40 sales on Form 4. The insider trading page charts every trade.
When is Privia Health Group, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Privia Health Group, Inc. announces its own schedule.